Inovio Pharmaceuticals
Corporate brand
UnclaimedInovio Pharmaceuticals is a biotechnology company developing synthetic DNA medicines and vaccines for cancer and infectious diseases.
Last updated October 31, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery and development of synthetic DNA medicines for cancer, infectious diseases, and other conditions involving the immune system. Its platform is designed to deliver engineered DNA sequences into cells, where the sequences are transcribed into messenger RNA and translated into proteins. Those proteins are intended to stimulate targeted immune responses, including the production of antigen-specific T cells and antibodies. The company originated in Oslo, Norway, in 1999 under the name Electrofect and adopted the Inovio name in October 2001. Its technology has centered on the combination of DNA medicine candidates with electroporation, an approach that uses a brief electrical pulse to create temporary pores in cell membranes. Inovio developed proprietary Cellectra devices to administer this electrical stimulus after injection. The company has described Cellectra as a portable delivery system intended to improve cellular uptake of plasmid DNA, including in field or outbreak settings. Inovio's development portfolio has included candidates targeting human papillomavirus-associated disease, cancers, Middle East respiratory syndrome, Zika virus, and SARS-CoV-2. Its infectious-disease work gained significant public attention during the COVID-19 pandemic. After the SARS-CoV-2 genetic sequence became available in early 2020, the company announced the design of INO-4800, a DNA vaccine candidate. Chief executive Joseph Kim stated during a White House Coronavirus Task Force meeting that the initial design had been produced rapidly after the viral sequence was released. Inovio subsequently entered early-stage clinical studies in the United States and South Korea and formed development relationships with organizations including the Coalition for Epidemic Preparedness Innovations, the International Vaccine Institute, South Korean public-health institutions, and Beijing Advaccine Biotechnology. The pandemic also brought government support and scrutiny. In June 2020, the United States Department of Defense committed $71 million to further development and procurement of Cellectra devices, although later United States support for future Phase III development of INO-4800 was discontinued. Inovio continued to explore clinical development and partnership avenues outside the United States, including with Advaccine. Shareholders filed litigation in 2020 alleging that the company had exaggerated evidence for its COVID-19 vaccine; the allegation was reported as a lawsuit, not an established finding of wrongdoing. Inovio's business model is primarily based on research, clinical development, intellectual-property licensing, partnerships, and potential commercialization of its pipeline, rather than a broad marketed pharmaceutical portfolio. Its main strategic distinction is the attempt to combine programmable DNA medicines with an electroporation delivery system. The company has pursued therapeutic applications such as cancer immunotherapy and treatment of HPV-related disease, as well as preventive applications such as vaccines against emerging infectious diseases. Clinical-stage biotechnology development remains subject to trial results, regulatory decisions, manufacturing requirements, financing conditions, and collaboration agreements.
History
Inovio Pharmaceuticals traces its origins to Electrofect, a company founded in Oslo, Norway, in 1999. The company changed its name to Inovio in October 2001 as it developed a biotechnology platform based on synthetic DNA medicines and electroporation-based delivery. Rather than relying on conventional small-molecule drugs or traditional vaccine production, the platform uses engineered DNA sequences intended to instruct cells to produce selected proteins. Those proteins can act as antigens, stimulating immune responses directed toward cancer cells or infectious agents. A central component of Inovio's approach is electroporation. After a DNA construct is injected into tissue, a short electrical pulse temporarily increases cell-membrane permeability, allowing plasmid DNA to enter cells more efficiently. Inovio developed the Cellectra family of devices to provide this electrical pulse. The company has presented Cellectra as a portable and potentially field-deployable system, a feature particularly relevant to infectious-disease vaccination during outbreaks. Inovio also licensed patents and related technology covering delivery of gene-based therapeutics to skin and the use of electroporation for ex vivo, intratumoral, and intramuscular delivery. The company's research has covered both therapeutic and preventive applications. In cancer and HPV-related disease, Inovio has investigated DNA-based immunotherapies intended to generate cellular immune responses against disease-associated antigens. In infectious disease, it developed INO-4700, also known as GLS-5300, for Middle East respiratory syndrome. A Phase I dose-escalation study reported safety, predominantly mild symptoms, and immune responses in most participants after two vaccinations, with responses reported as durable for a year. Inovio also participated in early Zika vaccine research during the 2016 outbreak. Working with GeneOne Life Science, it initiated a human study of GLS-5700 in healthy adults and later conducted research involving participants in Puerto Rico using its Cellectra-3P delivery technology. These programs demonstrated the company's interest in rapidly adapting its DNA platform to emerging viral threats. The COVID-19 pandemic became the most visible period in Inovio's history. After the SARS-CoV-2 sequence was published in early 2020, the company announced that it had designed the DNA vaccine candidate INO-4800 and moved into preclinical and early human testing. Inovio received support from CEPI and established collaborations involving the International Vaccine Institute, South Korean health authorities, Seoul National University, and Beijing Advaccine Biotechnology. Phase I research began in the United States in April 2020, while a Phase I-II program was pursued in South Korea. The pandemic program brought both commercial attention and controversy. The Department of Defense committed $71 million in June 2020 for further development and procurement of Cellectra devices, but in 2021 it discontinued funding for future United States Phase III trials of INO-4800. Inovio subsequently considered conducting later-stage studies outside the United States and worked with Advaccine on potential Phase III development. Shareholders filed litigation in August 2020 alleging that the company had exaggerated evidence relating to the vaccine's efficacy. The litigation was a significant public controversy, but the available reference material does not establish the allegations as fact. In 2021, Inovio described preclinical work on INO-4802, a pan-SARS-CoV-2 DNA vaccine candidate designed around mutations shared by multiple variants. Across its history, the company has remained a research- and development-focused biotechnology enterprise whose prospects depend on clinical evidence, regulatory review, manufacturing scale, partnerships, and access to capital. Its defining technological identity is the combination of synthetic DNA medicines with proprietary electroporation devices.
- 2021
INO-4802 is presented as a pan-SARS-CoV-2 candidate
[1]Inovio announced preclinical results and planned early clinical development for a DNA vaccine designed to address common mutations among SARS-CoV-2 variants.
- 2020
INO-4800 COVID-19 program begins
[1]Inovio announced a DNA vaccine candidate after publication of the SARS-CoV-2 sequence and began early clinical testing in the United States and South Korea.
- 2020
Department of Defense supports Cellectra
[1]The United States Department of Defense committed $71 million toward further development and procurement of Cellectra devices.
- 2016
MERS and Zika programs advance into human research
[1]Inovio reported Phase I research for its MERS candidate INO-4700 and initiated human study of the Zika candidate GLS-5700.
- 2006
Electroporation-related technology is licensed
[1]Inovio licensed patented technology covering delivery of gene-based therapeutics and gene or drug delivery through several electroporation routes.
- 2001
Company adopts the Inovio name
[1]Electrofect was renamed Inovio in October 2001.
- 1999
Electrofect is founded
[1]The company that later became Inovio Pharmaceuticals was founded in Oslo, Norway, under the name Electrofect.
Products and positioning
A clinical-stage biotechnology company positioned around programmable synthetic DNA medicines, immune-response activation, and proprietary electroporation delivery technology.
COVID-19 DNA vaccine candidate · 2020
INO-4800
INO-4800 is Inovio's synthetic DNA vaccine candidate for SARS-CoV-2. The program entered Phase I testing in the United States in April 2020 and was also studied in a Phase I-II program in South Korea. Its development involved CEPI, South Korean research and public-health institutions, the International Vaccine Institute, and Beijing Advaccine. Later-stage United States government support was discontinued, and the company considered conducting Phase III development outside the United States.
Pan-SARS-CoV-2 DNA vaccine candidate · 2021
INO-4802
INO-4802 is a DNA vaccine candidate designed around mutations shared by SARS-CoV-2 variants of concern. Inovio reported preclinical work in 2021 and described plans for Phase I/II research. The candidate reflects the company's strategy of using programmable DNA constructs to address evolving viral targets.
MERS vaccine candidate · 2016
INO-4700 (GLS-5300)
INO-4700, also known as GLS-5300, is a synthetic DNA vaccine candidate developed against Middle East respiratory syndrome coronavirus. In a 2016 Phase I dose-escalation study in healthy adults, the candidate was reported to be safe, with mostly mild symptoms, and to generate immune responses in more than 85 percent of participants after two vaccinations. Reported responses remained detectable one year later.
Zika vaccine candidate · 2016
GLS-5700
GLS-5700 is a DNA vaccine candidate developed for Zika virus in collaboration with GeneOne Life Science. Inovio and its partners initiated a human study in healthy adults to evaluate safety, tolerability, and immunogenicity, and conducted additional research in Puerto Rico using the Cellectra-3P delivery system.
Electroporation injection device
Cellectra
Cellectra is Inovio's proprietary electroporation delivery system. The device applies a brief electrical pulse after injection to temporarily open pores in cell membranes, facilitating entry of plasmid DNA into cells. Inovio developed handheld versions intended for use outside conventional clinical infrastructure, including outbreak-response settings. The Department of Defense supported further development and procurement of the device in 2020.
Controversies
2020
Shareholder lawsuit concerning COVID-19 vaccine claims
Shareholders sued Inovio in August 2020, alleging that the company exaggerated evidence concerning the efficacy of its coronavirus vaccine candidate to support its stock price. The reference material reports the lawsuit but does not establish the allegations as proven.
Marketing campaigns
- 2020COVID-19 vaccine development program
United States · South Korea · China · International
Following release of the SARS-CoV-2 sequence, Inovio developed INO-4800 and pursued funding, clinical research, manufacturing relationships, and regulatory collaboration with CEPI, South Korean institutions, the International Vaccine Institute, and Beijing Advaccine. The program advanced into early human studies, but United States Department of Defense funding for future Phase III trials was discontinued in 2021. The reference material does not identify a commercial approval.
Outcome. The program advanced into early human studies, but United States Department of Defense funding for future Phase III trials was discontinued in 2021. The reference material does not identify a commercial approval.
- 2016Zika vaccine response program
United States · Puerto Rico
Inovio and GeneOne Life Science pursued an early human DNA vaccine study for Zika during the outbreak period. The work included a study in healthy adults and research in Puerto Rico using Cellectra-3P. The program generated early human safety, tolerability, and immunogenicity data; the reference material does not establish a licensed commercial vaccine.
Outcome. The program generated early human safety, tolerability, and immunogenicity data; the reference material does not establish a licensed commercial vaccine.
Brand decisions
2021
Pursuit of non-United States later-stage INO-4800 trialsStrategyBackground
The United States Department of Defense discontinued funding for future Phase III trials of INO-4800.
Action taken
Inovio planned to pursue Phase III development outside the United States and identified Beijing Advaccine as a potential development partner.
Aftermath
The shift increased the importance of international clinical and regulatory partnerships for the candidate's continued development.
2020
Initiation of INO-4800 clinical developmentProduct launchBackground
The COVID-19 pandemic created an urgent need for vaccine candidates after the SARS-CoV-2 genetic sequence became available.
Action taken
Inovio advanced its synthetic DNA candidate INO-4800 into Phase I testing in the United States and early-stage research in South Korea.
Aftermath
The program received international partnerships and government attention but did not receive continued United States Department of Defense funding for future Phase III trials.
2020
Expansion of Cellectra manufacturing and deployment plansStrategyBackground
Inovio sought to make its DNA vaccine platform usable in epidemic conditions and outside conventional medical facilities.
Action taken
The company developed a handheld Cellectra device and received Department of Defense support for further development and procurement.
Aftermath
The funding supported the delivery-device program, while the wider vaccine development strategy remained dependent on clinical and regulatory progress.
Department of Defense commitment. $71 million (June 2020)
Recent events
- Unconfirmed
Reported
FDA approves Inovio treatment for rare throat disease[2]
The US FDA approved Inovio's treatment for a rare throat disease.
Reported
INOVIO and Colombia sign a collaboration MOU[3]
INOVIO announced that it had signed a non-binding memorandum of understanding with Colombia's Ministry of Health and Social Protection to establish a framework for exploring knowledge sharing, technology licensing, and capacity building related to vaccines and other biopharmaceuticals in Colombia.
Reported
Inovio and Advaccine expand vaccine-study partnership[4]
Inovio Pharmaceuticals expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate. The expanded deal gives Advaccine rights to additional Asian countries outside Greater China, and the companies expect to share the trial costs equally.
Reported
INOVIO and Advaccine expand partnership for global Phase 3 trial[5]
INOVIO and Advaccine announced an expansion of their partnership to jointly conduct a global Phase 3 segment of the INO-4800 COVID-19 vaccine trial. The trial was planned to begin that summer and to be conducted primarily in Latin America and Asia.
Reported
INOVIO prices public offering of common stock[6]
INOVIO announced the pricing of an underwritten public offering of 17.7 million common shares at $8.50 per share. The company said gross proceeds were expected to be approximately $150.5 million before expenses, excluding any exercise of the underwriters’ option.
Reported
Inovio and Advaccine enter China licensing agreement for INO-4800[7]
Inovio entered a licensing agreement with Advaccine for manufacturing and selling its INO-4800 vaccine candidate in China. Advaccine received exclusive rights in China.
Reported
INOVIO and Thermo Fisher sign vaccine manufacturing letter of intent[8]
INOVIO announced that Thermo Fisher Scientific had signed a letter of intent to manufacture INOVIO's INO-4800 COVID-19 vaccine candidate, including drug-substance production and fill-and-finish work at US facilities.
Reported
INOVIO works with IVI and KNIH on South Korean vaccine trial[9]
CEPI granted $6.9 million in funding to INOVIO to work with the International Vaccine Institute and Korea National Institute of Health on a Phase 1/2 clinical trial of INOVIO’s COVID-19 vaccine candidate, INO-4800, in South Korea.
Sources9 sources
- 1Inovio Pharmaceuticalsen.wikipedia.org
- 2FDA批准Inovio治疗罕见喉部疾病的疗法news.google.com
- 3INOVIO与哥伦比亚签署合作谅解备忘录us.acrofan.com
- 4Inovio与Advaccine扩大疫苗研究合作yahoo.com
- 5INOVIO与Advaccine扩大合作以开展全球III期试验biospace.com
- 6INOVIO为普通股公开发行定价prnewswire.com
- 7Inovio 与 Advaccine 就 INO-4800 达成中国许可协议yahoo.com
- 8INOVIO与赛默飞世尔签署疫苗制造意向书finanznachrichten.de
- 9INOVIO 与 IVI 和 KNIH 合作开展韩国疫苗试验finanznachrichten.de
Cite this profile: Cite the canonical profile. /brand-wiki/inovio-pharmaceuticals · Editorial policy · How profiles are compiled